

That which is claimed is:

- Sub a2*
1. A unit dosage form comprising a vessel containing a sufficient quantity of taxane to provide for administration to a subject at a total dose in the range of about 30 mg/m² to about 1000 mg/m² over an administration period no greater than about 3 hours.
 2. A unit dosage form according to claim 1, wherein said total dose is in the range of about 80 mg/m² to about 700 mg/m².
 3. A unit dosage form according to claim 1, wherein said total dose is in the range of about 50 mg/m² to about 800 mg/m².
 - same* 4. A unit dosage form according to claim 1, wherein said total dose is in the range of about 50 mg/m² to about 800 mg/m².
 5. A unit dosage form according to claim 1, wherein said total dose is in the range of about 60 mg/m² to about 400 mg/m².
 6. A unit dosage form according to claim 1, wherein said total dose is in the range of about 65 mg/m² to about 400 mg/m².
 7. A unit dosage form according to claim 1, wherein said total dose is in the range of about 70 mg/m² to about 400 mg/m².
 8. A unit dosage form according to claim 1, wherein said total dose is in the range of about 85 mg/m² to about 375 mg/m².
 9. A unit dosage form according to claim 1, wherein said total dose is in the range of about 100 mg/m² to about 300 mg/m².
 10. A unit dosage form according to claim 1, wherein said subject is human.
 11. A unit dosage form according to claim 1, wherein the cycle time between administrations of said total dose is less than about three weeks.
 12. A unit dosage form according to claim 1, wherein said taxane is administered locally.
 13. A unit dosage form according to claim 1, wherein said taxane is administered systemically.

14. A unit dosage form according to claim 1, wherein said taxane is in a non-aqueous formulation.
15. A unit dosage form according to claim 1, wherein said taxane is paclitaxel.
16. A unit dosage form according to claim 1, wherein said taxane^{is} a paclitaxel analog.
17. A unit dosage form comprising a vessel containing a sufficient quantity of docetaxel to provide for administration to a subject at a total dose in the range of about 40 mg/m² to about 800 mg/m² over an administration period no greater than about 3 hours.
18. A unit dosage form according to claim 17, wherein said total dose is in the range of about 50 mg/m² to about 800 mg/m².
19. A unit dosage form according to claim 17, wherein said total dose is in the range of about 60 mg/m² to about 400 mg/m².
20. A unit dosage form according to claim 17, wherein said total dose is in the range of about 65 mg/m² to about 400 mg/m².
21. A unit dosage form according to claim 17, wherein said total dose is in the range of about 80 mg/m² to about 700 mg/m².
22. A unit dosage form according to claim 17, wherein said total dose is in the range of about 70 mg/m² to about 400 mg/m².
23. A unit dosage form according to claim 17, wherein said total dose is in the range of about 85 mg/m² to about 375 mg/m².
24. A unit dosage form according to claim 17, wherein said total dose is in the range of about 100 mg/m² to about 300 mg/m².
25. A unit dosage form according to claim 17, wherein said subject is human.
26. A unit dosage form according to claim 17, wherein the cycle time between administrations of said total dose is less than about three weeks.
27. A unit dosage form according to claim 17, wherein said docetaxel is administered locally.

41. A unit dosage form according to claim 30, wherein said taxane is in a non-aqueous formulation.
42. A unit dosage form according to claim 30, wherein said taxane is in a formulation containing less than about 10% ethanol.
43. A unit dosage form according to claim 30, wherein said taxane is paclitaxel.
44. A unit dosage form according to claim 30, wherein said taxane is a paclitaxel analog.
45. A unit dosage form comprising a vessel containing a sufficient quantity of docetaxel to provide for administration to a subject at a total dose in the range of about 40 mg/m² to about 800 mg/m² with a cycle time of no greater than about three weeks between administrations of said total dose.
46. A unit dosage form according to claim 45, wherein said total dose is in the range of about 50 mg/m² to about 800 mg/m².
47. A unit dosage form according to claim 45, wherein said total dose is in the range of about 60 mg/m² to about 400 mg/m².
48. A unit dosage form according to claim 45, wherein said total dose is in the range of about 65 mg/m² to about 400 mg/m².
49. A unit dosage form according to claim 45, wherein said total dose is in the range of about 80 mg/m² to about 700 mg/m².
50. A unit dosage form according to claim 45, wherein said total dose is in the range of about 70 mg/m² to about 400 mg/m².
51. A unit dosage form according to claim 45, wherein said total dose is in the range of about 85 mg/m² to about 375 mg/m².
52. A unit dosage form according to claim 45, wherein said total dose is in the range of about 100 mg/m² to about 300 mg/m².
53. A unit dosage form according to claim 45, wherein said subject is human.

54. A unit dosage form according to claim 45, wherein said docetaxel is administered locally.
55. A unit dosage form according to claim 45, wherein said docetaxel is administered systemically.
56. A unit dosage form according to claim 45, wherein said docetaxel is in a non-aqueous formulation.
57. A unit dosage form according to claim 45, wherein said docetaxel is in a formulation containing less than about 10% ethanol.
58. A unit dosage form comprising a vessel containing a sufficient quantity of taxane to provide for administration to a subject at a total dose in the range of about 30 mg/m² to about 1000 mg/m², wherein said vessel comprises in the range of about 4 mg to about 822 mg of said taxane.
59. A unit dosage form according to claim 58, wherein said vessel comprises in the range of about 4 mg to about 13 mg of said taxane.
60. A unit dosage form according to claim 58, wherein said vessel comprises in the range of about 13 mg to about 30 mg of said taxane.
61. A unit dosage form according to claim 58, wherein said vessel comprises in the range of about 20 mg to about 69 mg of said taxane.
62. A unit dosage form according to claim 58, wherein said vessel comprises in the range of about 45 mg to about 69 mg of said taxane.
63. A unit dosage form according to claim 58, wherein said vessel comprises in the range of about 69 mg to about 90 mg of said taxane.
64. A unit dosage form according to claim 58, wherein said vessel comprises in the range of about 69 mg to about 103 mg of said taxane.
65. A unit dosage form according to claim 58, wherein said vessel comprises in the range of about 103 mg to about 120 mg of said taxane.

66. A unit dosage form according to claim 58, wherein said vessel comprises in the range of about 103 mg to about 148 mg of said taxane.
67. A unit dosage form according to claim 58, wherein said vessel comprises in the range of about 120 mg to about 367 mg of said taxane.
68. A unit dosage form according to claim 58, wherein said vessel comprises in the range of about 148.1 mg to about 367 mg of said taxane.
69. A unit dosage form according to claim 58, wherein said vessel comprises in the range of about 367 mg to about 548 mg of said taxane.
70. A unit dosage form according to claim 58, wherein said vessel comprises in the range of about 367 mg to about 822 mg of said taxane.
71. A unit dosage form according to claim 58, wherein the administration period for delivering said total dose is no greater than about 3 hours.
72. A unit dosage form according to claim 58, wherein the cycle time between administrations of said taxane is less than about three weeks.
73. A unit dosage form according to claim 58, wherein said subject is human.
74. A unit dosage form according to claim 58, wherein said taxane is administered locally.
75. A unit dosage form according to claim 58, wherein said taxane is administered systemically.
76. A unit dosage form according to claim 58, wherein said taxane is in a non-aqueous formulation.
77. A unit dosage form according to claim 58, wherein said taxane is paclitaxel.
78. A unit dosage form according to claim 58, wherein said taxane is a paclitaxel analog.
79. A unit dosage form comprising a vessel containing a sufficient quantity of docetaxel to provide for administration to a subject at a total dose in the range of about 30 mg/m² to about 1000 mg/m², wherein said vessel comprises a unit dose in the range of about 4 mg to about 822 mg of said docetaxel.

80. A unit dosage form according to claim 79, wherein said vessel comprises in the range of about 4 mg to about 13 mg of said docetaxel.
81. A unit dosage form according to claim 79, wherein said vessel comprises in the range of about 13 mg to about 30 mg of said docetaxel.
82. A unit dosage form according to claim 79, wherein said vessel comprises in the range of about 20 mg to about 69 mg of said docetaxel.
83. A unit dosage form according to claim 79, wherein said vessel comprises in the range of about 45 mg to about 69 mg of said docetaxel.
84. A unit dosage form according to claim 79, wherein said vessel comprises in the range of about 69 mg to about 90 mg of said docetaxel.
85. A unit dosage form according to claim 79, wherein said vessel comprises in the range of about 69 mg to about 103 mg of said docetaxel.
86. A unit dosage form according to claim 79, wherein said vessel comprises in the range of about 103 mg to about 120 mg of said docetaxel.
87. A unit dosage form according to claim 79, wherein said vessel comprises in the range of about 103 mg to about 148 mg of said docetaxel.
88. A unit dosage form according to claim 79, wherein said vessel comprises in the range of about 120 mg to about 367 mg of said docetaxel.
89. A unit dosage form according to claim 79, wherein said vessel comprises in the range of about 148 mg to about 367 mg of said docetaxel.
90. A unit dosage form according to claim 79, wherein said vessel comprises in the range of about 367 mg to about 548 mg of said docetaxel.
91. A unit dosage form according to claim 79, wherein said vessel comprises in the range of about 367 mg to about 822 mg of said docetaxel.
92. A unit dosage form according to claim 79, wherein the administration period for delivering said docetaxel is no greater than about 3 hours.

- 11

118. A unit dosage form according to claim 116, wherein said taxane is paclitaxel.
119. A unit dosage form according to claim 116, wherein said taxane is a paclitaxel analog.
120. A unit dosage form comprising a vessel containing a sufficient quantity of docetaxel to provide for administration to a subject at a total dose in the range of about 30 mg/m² to about 1000 mg/m², wherein said unit dosage form is useful for the treatment of metastatic tumors.
121. A unit dosage form according to claim 120, wherein said total dose is in the range of about 70 mg/m² to about 400 mg/m².
122. A unit dosage form comprising a vessel containing a quantity of a formulation of taxane sufficient to provide for administration to a subject at a total dose in the range of about 30 mg/m² to about 1000 mg/m², wherein said formulation does not leach plasticizer from administration devices used to administer said unit dosage formulation.
123. A unit dosage form according to claim 122, wherein said total dose is in the range of about 70 mg/m² to about 400 mg/m².
124. A unit dosage form according to claim 122, wherein said taxane is paclitaxel.
125. A unit dosage form according to claim 122, wherein said taxane is a paclitaxel analog.
126. A unit dosage form comprising a vessel containing a quantity of a formulation of docetaxel sufficient to provide for administration to a subject at a total dose in the range of about 30 mg/m² to about 1000 mg/m², wherein said formulation does not leach plasticizer from administration devices used to administer said unit dosage formulation.
127. A unit dosage form according to claim 126, wherein said total dose is in the range of about 70 mg/m² to about 400 mg/m².
128. A taxane containing formulation suitable for the delivery of a total dose of taxane in the range of about 30 mg/m² to about 1000 mg/m², with an administration period of no greater than about 3 hours.
129. A formulation according to claim 128, wherein said total dose of taxane is in the range of about 80 mg/m² to about 700 mg/m².
130. A formulation according to claim 128, wherein said taxane is paclitaxel.

131. A formulation according to claim 128, wherein said taxane is a paclitaxel analog.
132. A docetaxel containing formulation suitable for the delivery of a total dose of docetaxel in the range of about 80 mg/m^2 to about 700 mg/m^2 , with an administration period of no greater than about 3 hours.
133. A taxane containing formulation suitable for the delivery of a total dose of taxane in the range of about 80 mg/m^2 to about 700 mg/m^2 , with a treatment cycle of no greater than about 3 weeks.
134. A formulation according to claim 133, wherein said taxane is paclitaxel.
135. A formulation according to claim 133, wherein said taxane is a paclitaxel analog.
136. A docetaxel containing formulation suitable for the delivery of a total dose of docetaxel in the range of about 80 mg/m^2 to about 700 mg/m^2 , with a treatment cycle of no greater than about 3 weeks.
-
137. A unit dosage form comprising a vessel containing a sufficient quantity of taxane to allow systemic administration to a subject, employing a standard intravenous infusion set, of a total dose in the range of about 30 mg/m^2 to about 1000 mg/m^2 of said taxane.
138. A unit dosage form according to claim 137, wherein said infusion set is polyolefin.
139. A unit dosage form according to claim 138, wherein said polyolefin is polyethylene.
140. A unit dosage form according to claim 137, wherein said taxane is paclitaxel.
141. A unit dosage form according to claim 137, wherein said taxane is a paclitaxel analog.
142. A unit dosage form comprising a vessel containing a sufficient quantity of docetaxel to allow systemic administration to a subject, employing a standard intravenous infusion set, of a total dose in the range of about 30 mg/m^2 to about 1000 mg/m^2 of said docetaxel.
143. A unit dosage form according to claim 142, wherein said infusion set is polyolefin.
144. A unit dosage form according to claim 143, wherein said polyolefin is polyethylene.

- Sub B22*
145. A method for administration of taxane to a subject in need thereof, said method comprising administering in the range of about 30 mg/m² to about 1000 mg/m² of said taxane to said subject in a pharmaceutically acceptable formulation with a treatment cycle no greater than about 3 weeks.
146. A method according to claim 145, wherein said taxane is paclitaxel.
147. A method according to claim 145, wherein said taxane is a paclitaxel analog.
- Sub B23*
148. A method for administration of docetaxel to a subject in need thereof, said method comprising administering in the range of about 30 mg/m² to about 1000 mg/m² of said docetaxel to said subject in a pharmaceutically acceptable formulation with a treatment cycle no greater than about 3 weeks.
149. A method for administration of taxane to a subject in need thereof, said method comprising administering in the range of about 30 mg/m² to about 1000 mg/m² of said taxane to said subject in a pharmaceutically acceptable formulation with an administration period no greater than about 3 hours.
150. A method according to claim 149, wherein said taxane is paclitaxel.
151. A method according to claim 149, wherein said taxane is a paclitaxel analog.
152. A method for administration of docetaxel to a subject in need thereof, said method comprising administering in the range of about 30 mg/m² to about 1000 mg/m² of said docetaxel to said subject in a pharmaceutically acceptable formulation with an administration period no greater than about 3 hours.
153. A method for administration of taxane to a subject in need thereof, said method comprising administering in the range of about 30 mg/m² to about 1000 mg/m² of said taxane to said subject in a pharmaceutically acceptable formulation, wherein the treatment of said subject receiving said taxane does not include the administration of agents which aid in the recovery from hematologic toxicity.
154. A method according to claim 153, wherein said agent is a cytokine.
155. A method for administration of docetaxel to a subject in need thereof, said method comprising administering in the range of about 30 mg/m² to about 1000 mg/m² of said

001000 1000000000

docetaxel to said subject in a pharmaceutically acceptable formulation, wherein the treatment of said subject receiving said docetaxel does not include the administration of cytokines.

156. A method for administration of taxane to a subject in need thereof, said method comprising administering a unit dosage form comprising a vessel containing a sufficient quantity of taxane to provide for administration to a subject at a total dose in the range of about 30 mg/m² to about 1000 mg/m², wherein said taxane remains stable for greater than about 24 hours and less than about 3 days following addition thereto of an aqueous diluent.
157. A method according to claim 156, wherein said taxane is paclitaxel.
158. A method according to claim 156, wherein said taxane is a paclitaxel analog.
159. A method for administration of docetaxel to a subject in need thereof, said method comprising administering a unit dosage form comprising a vessel containing a sufficient quantity of docetaxel to provide for administration to a subject at a total dose in the range of about 30 mg/m² to about 1000 mg/m², wherein said docetaxel remains stable for greater than about 24 hours and less than about 3 days following addition thereto of an aqueous diluent.
160. A method for administration of taxane to a subject in need thereof, said method comprising administering a unit dosage form comprising a vessel containing a sufficient quantity of taxane to provide for administration to a subject at a total dose in the range of about 30 mg/m² to about 1000 mg/m², wherein refrigeration does not adversely affect the stability of said taxane.
161. A method according to claim 160, wherein said taxane is paclitaxel.
162. A method according to claim 160, wherein said taxane is a paclitaxel analog.
163. A method for administration of docetaxel to a subject in need thereof, said method comprising administering a unit dosage form comprising a vessel containing a sufficient quantity of docetaxel to provide for administration to a subject at a total dose in the range of about 30 mg/m² to about 1000 mg/m², wherein refrigeration does not adversely affect the stability of said docetaxel.

164. A method for treatment of primary tumors, said method comprising administration to a subject in need thereof a unit dosage form comprising a vessel containing a sufficient quantity of taxane to provide for administration to a subject at a total dose in the range of about 30 mg/m² to about 1000 mg/m².
165. A method for treatment of primary tumors, said method comprising administration to a subject in need thereof a unit dosage form comprising a vessel containing a sufficient quantity of docetaxel to provide for administration to a subject at a total dose in the range of about 30 mg/m² to about 1000 mg/m².
166. A method for treatment of metastatic tumors, said method comprising administration to a subject in need thereof a unit dosage form comprising a vessel containing a sufficient quantity of taxane to provide for administration to a subject at a total dose in the range of about 30 mg/m² to about 1000 mg/m².
167. A method for treatment of metastatic tumors, said method comprising administration to a subject in need thereof a unit dosage form comprising a vessel containing a sufficient quantity of docetaxel to provide for administration to a subject at a total dose in the range of about 30 mg/m² to about 1000 mg/m².
168. A method for administration of taxane to a subject in need thereof, said method comprising administering a unit dosage form comprising a vessel containing a sufficient quantity of taxane to provide for administration to a subject at a total dose in the range of about 30 mg/m² to about 1000 mg/m², wherein said taxane does not leach plasticizer from administration devices used to administer said unit dosage formulation.
169. A method for administration of docetaxel to a subject in need thereof, said method comprising administering a unit dosage form comprising a vessel containing a sufficient quantity of docetaxel to provide for administration to a subject at a total dose in the range of about 30 mg/m² to about 1000 mg/m², wherein said docetaxel does not leach plasticizer from administration devices used to administer said unit dosage formulation.
170. A method for administration of taxane to a subject in need thereof, said method comprising administering a unit dosage form comprising a vessel containing a sufficient quantity of taxane to provide for administration to a subject at a total dose in the range of about 30 mg/m² to about 1000 mg/m², wherein said unit dosage form confers reduced

incidence of hypersensitivity as compared to a subject receiving a formulation containing a cremophor.

171. A method for administration of docetaxel to a subject in need thereof, said method comprising administering a unit dosage form comprising a vessel containing a sufficient quantity of docetaxel to provide for administration to a subject at a total dose in the range of about 30 mg/m² to about 1000 mg/m², wherein said unit dosage form confers reduced incidence of hypersensitivity as compared to a subject receiving a formulation containing a cremophor.

0011000-2822300